Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...
Cancer
Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...
Ambrx Biopharma Halts Development of HER2 ADC ARX788, Cuts Workforce
US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...
Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...
Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...
HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments
China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...
GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of...
Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...
Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion
Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised...
Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients
China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion...
Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products...
Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma
China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...
Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND)...
Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform
China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic...
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
Genor Biopharma Initiates First Patient Dosing for GB263T in China
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a...
Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study
China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...
BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...